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Abstract
Hepatitis B virus X protein (HBx) plays important roles in the development of hepatocellular carcinoma (HCC). MicroRNAs
(miRNAs) contribute to cancer development by acting as oncogenes or tumor suppressors. Previously, we reported that HBx
was able to promote the migration of hepatoma HepG2 cells. However, the regulation of miRNAs in the development of
HBV-related HCC is poorly understood. In the present study, we reported that miR-29a was a novel regulator of migration of
hepatoma cells mediated by HBx. Our data showed that the expression of miR-29a was dramatically increased in p21-HBx
transgenic mice, HBx-transfected hepatoma HepG2-X (or H7402-X) cells and HepG2.2.15 cells that constitutively replicate
HBV. However, our data showed that miR-29a was upregulated in 4 of the 11 clinical HCC samples. We found that the
overexpression of miR-29a promoted the migration of HepG2 cells, while a specific miR-29a inhibitor could partially abolish
the enhanced migration of HepG2-X cells. Moreover, we identified PTEN was one of the target genes of miR-29a in HepG2
cells. The deletion of the miR-29a-binding site was able to abolish the role of miR-29a in suppression of luciferase activity of
the PTEN 39UTR reporter. Meanwhile, the overexpression of PTEN was able to reverse the promoted migration of HepG2
cells mediated by miR-29a. Moreover, our data showed that the modulation of Akt phosphorylation, a downstream factor of
PTEN, was involved in the cell migration enhanced by miR-29a, suggesting that miR-29a is responsible for the cell migration
through its target gene PTEN. Thus, we conclude that miR-29a is involved in the regulation of migration of hepatoma cells
mediated by HBx through PTEN in cell culture model.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignant tumors in the world. Among the well known risk factors
for HCC, chronic infection with hepatitis B (HBV) or C (HCV)
virus is present in more than 85% of primary liver cancers [1]. The
HBV X protein (HBx), an essential factor for HBV replication, is
thought to play a key role in the molecular pathogenesis of HBV-
related HCC (HBV-HCC) [2]. Previous study revealed that HBx
knocked into the p21 locus caused hepatocellular carcinoma in
mice [3]. Our laboratory has focused on the investigation of
hepatocarcinogenesis mediated by HBx. Our and other reports
have demonstrated that HBx is able to promote migration and
invasion of hepatoma cells by upregulation of osteopontin, Capn4,
matrix metalloproteinases, MIG, and deregulation of intercellular
adhesion [4,5,6,7]. However, a comprehensive understanding of
the underlying mechanism by which HBx promotes migration
needs further elucidation.
MicroRNAs (miRNAs) are evolutionary conserved small
RNAs affecting gene expression at the posttranscriptional level
through translational repression and/or target messenger RNAs
degradation in a sequence-dependent manner [8]. Recent studies
have revealed that miRNAs participate in many cellular
processes including proliferation, development, differentiation,
or even in tumorigenesis [9]. Alterations of the expression
patterns of miRNAs have been found in different human tumors
[10]. Despite the growing evidence for their importance in
carcinogenesis, limited information is available about their
function in HBV-HCC. Previously, miR-29a was implicated in
chronic lymphocytic leukaemia, cholangio carcinoma and lung
cancer by deregulation of its target gene Tcl1 and DNMT3 as a
tumor suppressor [11,12]. However, it is also reported that miR-
29a promote tumorigenesis in breast cancer and acute myeloid
leukemia [13,14], and recently, Santanam U et al. reported that
overexpressing miR-29 in mouse B cells contributes to B-cell
chronic lymphocytic leukemia in transgenic mouse model [15].
These studies suggest a context-dependent pattern for miR-29a
in tumorigenicity.
Phosphatase and tensin homolog (PTEN) is a protein and
phosphoinositide phosphatase which is originally identified as a
tumor suppressor frequently mutated or deleted in various
human cancers to promote tumorigenesis [16,17]. Interestingly,
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sion in hepatocytes, rather than PTEN mutations or deletions,
represents a critical factor in the development of HCC. It has
been reported that PTEN is downregulated in HCC patients by
immunohistochemistry assay [18]. PTEN was indicated to be
able to inhibit migration through regulation of PI3K/Akt
pathway or SRC family kinases [19,20]. PTEN was also shown
to be a direct target of miR-21 and miR-221& 222, and
contribute to cell migration [21,22]. However, whether other
miRNAs are also involved in the regulation of PTEN remains
unclear.
In the present study, we sought to gain insight into the
regulation of miR-29a in HBV-HCC. Our finding shows that
miR-29a is able to directly regulate PTEN in the promotion of
hepatoma cell migration mediated by HBx. Our data provide new
insights into the mechanism of promotion of hepatoma cell
migration induced by HBx.
Results
MiR-29a is upregulated in the p21-HBx transgenic mice
and stable HBx-transfected hepatoma cells
To gain insight into the biological role of HBx in miRNA
expression pattern, we analyzed the expression of miR-29a in p21-
HBx transgenic mice by quantitative reverse-transcription PCR
(qRT-PCR). HBx gene knock-in transgenic mouse model (termed
p21-HBx transgenic mice) was generated by homologous recom-
bination. HBx gene was integrated into the mouse p21 locus. Both
male and female p21-HBx transgenic mice developed HCC after
the age of 18 months [3]. We compared the miR-29a expression of
transgenic mouse liver tissues with wild type mice of the same
strain (C57BL/6), sex, and age (6 months old) and found that miR-
29a was significantly upregulated in the transgenic mice (Fig. 1A).
Next, we determined whether miR-29a was expressed differently
in human hepatoma cells with stable HBx expression. Previously,
Figure 1. HBx upregulates miR-29a. (A) The relative expression of miR-29a for 6-month-old p21-HBx transgenic mice versus WT mice was
detected by qRT-PCR. (B) The expression of miR-29a in stable HBx-transfected hepatoma cell lines was examined by qRT-PCR. (C) The expression
levels of miR-29a in HepG2-X (or H7402-X) were examined by qRT-PCR after treatment with HBx RNAi in a dose dependent manner. (D) The relative
expression level of miR-29a in HepG2.2.15 cells was examined by qRT-PCR. Plotted are the means 6 SD of three samples normalized to U6.
Statistically significant differences, arbitrarily set to 1.0, are indicated: *P,.05, **P,.01, Student’s t test.
doi:10.1371/journal.pone.0019518.g001
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H7402-X) which was stably transfected with HBx, and HepG2-P
(or H7402-P) which was stably transfected with an empty
pcDNA3.0 vector [23]. Then, we found that miR-29a was
upregulated in both HepG2-X and H7402-X cells (Fig. 1B). In
order to further verify whether this upregulation correlated with
the HBx expression, we also examined the expression of miR-29a
after HBx knockdown by RNAi. The results showed that the miR-
29a expression was reduced after HBx knockdown in a dose
dependent manner (Fig. 1C). Moreover, we showed that the miR-
29a expression level was upregulated in HepG2.2.15 cells that
constitutively replicate HBV relative to HepG2 cells (Fig. 1D). All
the data strongly support that HBx upregulates the expression of
miR-29a.
To determine whether miR-29a was expressed differentially in
human primary liver cancer tissues, we measured the miR-29a
expression levels in 11 pairs of human HCC tissues and peritumor
tissues by qRT-PCR (Table S2). The result showed that all clinical
HCC tissues and their peritumor tissues were positive for HBx
mRNA (Fig. S1A). However, among the 11 HBV-related HCC
samples analyzed, the miR-29a levels were only significantly
increased in 4 HCC samples in comparison with the adjacent
noncancerous hepatic tissues (Fig. S1B). Correlation between
expression levels of miR-29a and HBx in tissues was explored
using Pearson9s correlation coefficient, but no correlation was
observed.
MiR-29a promotes migration of hepatoma cells
We supposed that high expression of miR-29a may be
associated with migration capability of hepatoma cells. Therefore,
we tested the expression level of miR-29a using the hepatoma cell
lines which were reported with different metastasis potential as a
model, such as MHCC-97H and MHCC-97L [24]. The data
showed that the expression level of miR-29a was positively
correlated with the metastasis potential of the cells (Fig. S2A).
Then, we assessed the effect of miR-29a on the migration in
HepG2 cells by wound healing and modified Boyden’s chamber
assays. As shown in Fig. 2A and 2B, the overexpression of miR-
29a resulted in a remarkable increase in the cell migration ability
relative to the control group. The expression level of miR-29a was
examined by qRT-PCR after overexpression of miR-29a. The
data showed that the expression of miR-29a was significantly
increased, while the expression of miR-29c was not affected by the
treatment, suggesting that the overexpression of miR-29a is
specific (Figure 2C).
To test whether miR-29a regulates the migration of hepatoma
cells mediated by HBx, we used a miR-29a specific inhibitor to
block miR-29a expression in HepG2-X cells. Interestingly, wound
healing and modified Boyden’s chamber assays showed a
significant reduction of migration of HepG2-X cells after the
treatment (Fig. 2D and 2E). Meanwhile, we confirmed that the
miR-29a inhibitor did not affect the expression level of HBx
protein in HepG2-X cells (Fig. 2F). Thus, our finding reveals that
miR-29a is involved in the regulation of migration of hepatoma
cells mediated by HBx.
MiR-29a directly inhibits the expression of PTEN by
binding 39UTR of PTEN mRNA
To search for the miR-29a target genes, we identified two
regions complementary to its seed region in the 39UTR of human
PTEN mRNA using the DIANA microT v3.0 algorithm (Fig. 3A),
which was also confirmed by TargetScan and PicTar. To validate
whether miR-29a directly recognizes the 39UTR of PTEN mRNA
or not, firstly, we cloned two sequences with the predicted target
site of miR-29a (PTEN 39UTR-1 and PTEN 39UTR-2) or
predicted target site deleted sequences (PTEN 39UTR-1-del and
PTEN 39UTR-2-del) into downstream of the pGL3-control
luciferase reporter gene vector, respectively. When the PTEN
39UTR wild-type or deletion-type vector was cotransfected with
miR-29a, the luciferase activity of the PTEN 39UTR wild-type
vector was significantly decreased compared with the deletion-type
vector in a dose-dependent manner (Fig. 3B). Moreover, when
both miR-29a and the specific miR-29a inhibitor were cotrans-
fected with the PTEN 39UTR wild-type vector, the luciferase
activity of PTEN 39UTR wild-type vector was rescued by the
inhibitor of miR-29a in a dose dependent manner (Fig. 3C).
Furthermore, the overexpression of miR-29a was able to markedly
downregulate the expression of endogenous PTEN at the levels of
mRNA and protein in HepG2 or MHCC-97L cells. Meanwhile,
the miR-29a inhibitor was able to upregulate the expression of
PTEN at the levels of mRNA and protein (Fig. 3D). Moreover, the
relative expression levels of PTEN were examined by qRT-PCR in
11 clinical HCC tissues. The data showed that the expression level
of miR-29a was inversely correlated with the expression level of
PTEN (Fig. S2B), suggesting that miR-29a negatively regulates the
expression of PTEN by directly targeting the 39UTR of mRNA.
Previously, it was reported that HBx was able to decrease the
expression of PTEN [25]. Western blot analysis confirmed that
PTEN was downregulated in HepG2-X (or H7402-X) cells
relative to controls (Fig. S2C). While, knockdown HBx by RNAi
could increase the expression of PTEN in HepG2-X (or H7402-X)
cells in a dose dependent manner (Fig. S2D). Thus, our data are
consistent with the reports that HBx downregulates the expression
of PTEN. As expected, we showed that the levels of PTEN were
negatively correlated with the metastasis potential in a model of
MHCC-97H cells/MHCC-97L cells (Fig. S2E), suggesting that
PTEN is negatively associated with the expression of miR-29a. It
supports that PTEN is a target gene of miR-29a.
PTEN is involved in the enhanced migration of hepatoma
cells mediated by miR-29a
Accordingly, we identified that PTEN was a target gene of miR-
29a. It has been reported that PTEN is able to inhibit the
migration of hepatoma cells [21,22]. To further understand the
mechanism of miR-29a promoted migration, we examined the
effect of PTEN on the migration ability of HepG2 cells mediated
by miR-29a by knockdown the PTEN expression using siRNA.
The wound healing and modified Boyden’s chamber assays
showed that downregulation of PTEN was able to promote the
migration of HepG2 cells relative to control cells. Interestingly, the
overexpression of PTEN was able to abolish the enhanced
migration of HepG2 cells mediated by miR-29a by transient
transfection with pcDNA3-PTEN plasmid (Fig. 4A and 4B).
Western blot confirmed the expression of PTEN after the
transfection (Fig. 4C). Therefore, our finding suggests miR-29a
increases the migration of hepatoma cells through PTEN target
gene.
Akt phosphorylation is regulated by miR-29a through
PTEN
Protein kinase B (Akt) is a protein serine-threonine protein
kinase involved in the regulation of cell growth, cell survival, and
cell migration [19,26]. Expression of PTEN leads to dephosphor-
ylation of Akt and inhibition of cell migration. To confirm the role
of miR-29a in regulation of PTEN, we next assessed the role of
miR-29a on the expression of phosphorylated Akt, a downstream
effector of PTEN. We found that the transfection with miR-29a in
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19518Figure 2. MiR-29a increases the migration of hepatoma cells. (A) A wound healing assay was performed on HepG2 cells (1610
6, 6-cm plate)
transfected with either an empty vector (control) or a miR-29a expression vector (3 mg). One representative experiment is shown. Black arrows
indicate the wound edge. The residual gap between the migrating cells from the opposing wound edge is expressed as a percentage of the initial
scraped area. (B) Modified Boyden’s chamber assays showed that the cell migration was promoted by the miR-29a in HepG2 cells. A histogram shows
the relative cell number of five randomly selected fields. (C) The expression levels of miR-29a and miR-29c were examined by qRT-PCR after
overexpression of miR-29a in HepG2 cells. (D) A wound healing assay was performed on HepG2, HepG2-P and HepG2-X cells transfected with a miR-
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the level of serine phosphorylation of Akt at ser473 (Fig. 5A).
Moreover, the inhibitor of miR-29a significantly reduced the
phosphorylation of Akt in HCC cell lines (Fig. 5B). Meanwhile, we
showed that the treatment with PTEN siRNA could abolish the
inhibited phosphorylation of Akt mediated by miR-29a inhibitor
(Fig. 5C). Interestingly, wound healing assay showed that
knockdown of Akt by siRNA was able to abolish the enhanced
migration ability of HepG2 cells mediated by miR-29a (Fig. 5D).
The total Akt and the phosphorylation level of Akt were shown in
Fig. S3A.
It has been reported that MMP-2 is one of targets of miR-29b in
Hela cells and prostate cancer cells [27,28], so that we are
interested in the association of miR-29a and MMP-2. We assessed
the effect of miR-29a on the expression of MMPs. Surprisingly,
our data revealed that the transfection with miR-29a increased the
expression level of MMP-2 mRNA in HCC cell lines by real time
PCR (Fig. S3B and S3C). Whereas, the expression level of MMP-2
was decreased by the transfection with the miR-29a inhibitor in
the cells (Fig. S3D), suggesting that miR-29a is able to upregulate
MMP2.
Discussion
HBx is a multifunctional oncoprotein which plays many roles in
the development of HCC. HBx deregulates a wide variety of host
genes related to cell proliferation, cell cycle progress, apoptosis,
metastasis, protein degradation pathways and genetic stability [29].
Previous studies demonstrated that HBx is associated with HCC
cells migration [4,5,6,7]. Although these changes triggered by HBx
are known to be involved in the acquisition of metastatic properties,
the possible contribution of HBx to the development of HCC
remainsfar unclear. Recentstudies have shown that miRNAs play a
fundamental role in the invasion and metastasis of HCC [21],
thereby opening a novel avenue to investigate the molecular
mechanism of HCC progression and to develop potential
therapeutics against HCC. It is also reported that HBx is able to
upregulate miR-143 through NF-kB, which can promote HCC
metastasis in an athymic nude mouse model [30]. However, the
effect of miRNAs has not been explored extensively in HBV-HCC.
In our present study, we first found that miR-29a level was
upregulated in p21-HBx transgenic mice and varied significantly
between HepG2 (or H7402) cells with or without HBx stable
expression (Fig. 1A and 1C). Meanwhile, we found that miR-29a
was upregulated in HepG2.2.15 cells that constitutively replicate
HBV relative to HepG2 cells (Fig. 1D), which supports that HBx
upregulates miR-29a. However, our data showed that miR-29a
was upregulated in only 4 of the 11 clinical HCC samples (Fig.
S1B). Previous study reported that miR-29c was downregulated in
HBV/HCV positive HCC samples compared with normal tissues
[31]. We can not answer the controversial issue, so that we
consider that this can be partially explained by multifactorial
etiology of cancer and the complexity of clinical tissues. For
example, Ramiro Garzon et al. found that miR-29a was
downregulated in acute myeloid leukemia (AML) patients [32].
While, Yoon-Chi Han, et al. reported that miR-29a was
overexpressed in AML patients [14]. The similar phenomena
were observed for miR-34a in HCC patients [33,34]. In addition,
Santanam U et al. reported that miR-29a was upregulated in
indolent human B-cell chronic lymphocytic leukemia (B-CLL) as
compared with aggressive B-CLL and normal CD19+ B cells [15].
Thus, we speculate that miR-29a may express at different stages of
cancer development. Our finding suggests that the upregulation of
miR-29a may be involved in the development of HCC.
In addition, we also observed that the expression level of miR-
29a was higher in MHCC-97H cells compared with MHCC-97L
cells (Fig. S2A). As elevated miR-29a expression was found in
MHCC-97H which has high metastasis potential, we present a
hypothesis that miR-29a may contribute to sustain a high
migration ability mediated by HBx. Thus, we tested whether
miR-29a has the ability to enhance the migration of tumor cells.
We observed that miR-29a was able to promote the migration of
hepatoma cells. Then, we found a significant reduce of migration
after we added miR-29a inhibitor into HepG2-X cells (Fig. 2D
and 2E). Thus, we conclude that HBx increases the migration of
hepatoma cells through enhancing the expression of miR-29a,
which is consistent with the previous report that miR-29a promote
metastasis in breast cancer [13].
To better understand the underlying mechanism of miR-29a
induced hepatoma cell migration, we found that PTEN was
potentially a target gene of miR-29a using bioinformatics method
(Fig. 3A). We subsequently confirmed that PTEN was a direct
target of miR-29a, which was able to decrease PTEN expression at
both mRNA and protein levels (Fig. 3B, 3C, and 3D). Therefore,
PTEN is regulated by miR-29a besides miR-21 [21] and miR-
221&222 [22]. We tried to detect the expression of miR-21 and
miR-221 in HBx positive cells and in the p21-HBx transgenic mice.
The result showed that the expression of miR-21 and miR-221
was not affected by HBx. Previous study also showed that HBx was
able to downregulate PTEN expression in liver cells [25], which is
consistent with our report. Importantly, we found that PETN was
able to abolish the promoted migration of HepG2 cells mediated
by miR-29a (Fig. 4A and 4B), suggesting that miR-29a increases
the migration of tumor cells by PTEN target gene.
To demonstrate the role of miR-29a in regulation of PTEN, we
further examined the effect of miR-29a on the phosphorylation
level of Akt, a downstream target of PTEN. Interestingly, our data
showed that miR-29a was able to promote the phosphorylation of
Akt (Fig. 5A and 5B), supporting that miR-29a regulates PTEN. In
function, we showed that knockdown of Akt expression abolished
the increased migration ability mediated by miR-29a in HepG2
cells (Fig. 5D). It further supports that miR-29a promotes cell
migration through PTEN. Meanwhile, our data showed that miR-
29a upregulated the expression of MMP-2 (Fig. S3B and S3C).
However, previous studies reported that miR-29a targeted p85a
(the regulatory subunit of PI3 kinase), which may result in the
reduced phosphorylation of Akt [35]. It has also been reported
that MMP-2 is one of miR-29b targets in Hela cells and prostate
cancer cells [27,28]. One possible explanation is that it is due to a
context-dependent pattern for miR-29a in tumorigenicity. Many
studies demonstrated that a miRNA could be considered either as
a tumor suppressor or as an oncogene depending on its targets in
different tissues and cell types [9,36,37]. A recent study reported
that microRNA-340-mediated degradation of microphthalmia-
associated transcription factor mRNA was inhibited by the coding
29a inhibitor (100 nM) or inhibitor negative control (inhNC). One representative experiment is shown. Black arrows indicate the wound edge. The
residual gap between the migrating cells from the opposing wound edge is expressed as a percentage of the initial scraped area. (E) Modified
Boyden’s chamber assays showed that the cell migration was blocked by miR-29a inhibitor in HepG2-X cells. A histogram shows the relative cell
number of five randomly selected fields. (F) Western blot analysis showed that the expression of HBx protein was not affected by the treatment with
miR-29a inhibitor in HepG2-X cells. Statistically significant differences are indicated: *P,.05, **P,.01, Student’s t test.
doi:10.1371/journal.pone.0019518.g002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19518Figure 3. MiR-29a targets PTEN. (A) Sequence alignment between miR-29a and the 39UTR of human PTEN mRNA. Solid line, seed match region;
dashed line, seed-deleted region. (B) Luciferase reporter gene assay showed the effect of miR-29a on the activity of PTEN 39UTR reporter. Co-
transfection was performed using the plasmids, such as human PTEN 39UTR (PTEN 39UTR-1 or PTEN 39UTR-2) or the miR-29a-binding site-deleted (del)
PTEN 39UTR (PTEN 39UTR-1-del or PTEN 39UTR-2-del), a miR-29a expression plasmid (50, 100, and 200 ng), in HepG2 cells. Empty pcDNA3.0 plasmid
(200 ng) was used as a negative control. (C) Luciferase reporter gene assay showed that the decreased luciferase activities of PTEN 39UTR reporter
(PTEN 39UTR-1 or PTEN 39UTR-2) in HepG2 cells mediated by miR-29a overexpression (200 ng) was rescued by a miR-29a inhibitor in a dose
dependent manner (30, 50, and 100 nM). (D) Immunoblot and qRT-PCR showed that miR-29a (3 mg, 6-cm plate) induced a decrease in endogenous
human PTEN protein and mRNA in HepG2 and MHCC-97L cells, which was increased by transfection with a miR-29a inhibitor. GAPDH and b-actin
were used as internal controls. Protein bands were quantified using Quantity One software (Bio-Rad). The value under each lane indicates the relative
expression level of the PTEN, which is represented by the intensity ratio between PTEN and b-actin bands in each lane. Statistically significant
differences are indicated: *P,.05, **P,.01, Student’s t test.
doi:10.1371/journal.pone.0019518.g003
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mechanism that the interaction of miRNA and its target genes
could be prevented, resulting in stabilization of the target gene
transcript and elevated expression and transcriptional activity [38].
Thus, our findings suggest that miR-29a promotes hepatoma cell
migration through targeting PTEN involving the activation of
phosphorylated Akt and MMP-2.
Taken together, here we report that miR-29a is able to directly
regulate PTEN in the promotion of hepatoma cell migration
mediated by HBx. Thus, our finding provides new insights into the
regulation of altered miRNA expression in contributing to the
tumor phenotype.
Materials and Methods
Cell culture
HepG2, H7402, HepG2.2.15, MHCC-97L, MHCC-97H cells
were maintained in Dulbecco’s modified Eagle’s medium (Life
Technologies, Inc., Gaithersburg, MD) supplemented with 10%
fetal bovine serum (Life Technologies). The engineered cells of
HepG2-X/H7402-X (stably transfected with the pCMV-HBx
plasmid), and HepG2-P/H7402-P (stably transfected with the
empty pcDNA3.0 vector plasmid) were generated in HepG2 and
H7402 cells, respectively, using the Lipofectamine 2000 protocol
(Invitrogen, USA) as previously described [23].
Patient samples
The 11 clinical HCC tissues and the corresponding nearby
noncancerous livers used in this study were obtained from patients
who underwent radical resection at Tianjin First Center Hospital
(Tianjin, China). Tissues were snap frozen in liquid nitrogen.
Written consent approving the use of their tissues for research
purposes after operation was obtained from each patient. The
study was approved by the Institute Research Ethics Committee at
the Nankai University.
Figure 4. PTEN inhibits migration of tumor cells. (A) A wound healing assay was performed on HepG2 cells (1610
6, 6-cm plate) transfected
with random siRNA, PTEN siRNA, pcDNA3-29a, and both pcDNA3-PTEN/pcDNA3-29a, respectively. One representative experiment is shown. Black
arrows indicate the wound edge. (B) Modified Boyden’s chamber assays showed that enhanced cell migration induced by miR-29a was reversed by
the overexpression of PTEN in HepG2 cells. A histogram shows the relative cell number of five randomly selected fields. (C) The expression of PTEN
was detected by western blot analysis in above transfected HepG2 cells. Statistically significant differences are indicated: *P,.05, **P,.01, Student’s t
test.
doi:10.1371/journal.pone.0019518.g004
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PCR analysis (qRT-PCR)
Extraction of total RNA of the cells (or aged 6 month liver tissues
from p21-HBx transgenic mice [3]) and reverse transcription were
carried outasdescribedpreviously[39].FortissuesRNAextraction,
grind frozentissues toa fine powderusinga mortarandpestle under
liquid nitrogen quicklyand then treatedas cells. To quantify mature
miRNA expression,the totalRNAwas isolated bya modified Trizol
protocol. Total RNA was polyadenylated by poly (A) polymerase
(Ambion, Austin, TX). A 50 ml polyadenylation reaction was
generated using 10 mg total RNA and 1 ml (2U) poly (A) polymerase
according to the manufacturer’s protocol. The reaction was
incubated at 37uC for 60 min after which poly (A)-tailed total
RNA was recovered by phenol/chloroform extraction and ethanol
precipitation. Reverse transcription was performed using 1 mg poly
(A)-tailed total RNA, and 1 ml ImPro-II Reverse Transcriptase
(Promega, USA) according to manufacturer’s instructions. Quan-
titative real time PCR was performed using the quantitative SYBR
Green PCR kit (TaKaRa Bio, China). One primer is microRNA-
specific (Table S1), and the other is a universal primer (Table S1).
U6 small nuclear RNA and GAPDH were used for normalization
(Table S1). To examine the specificity of the qRT-PCR, the
dissociation curve analysis is performed after a completed PCR.
Primers used are listed in Table S1.
RNA interference
pSilencer-HBx was used to produce small interfering RNAs
(siRNAs) targeting HBx mRNA, and pSilencer-control was used as
negative control [40]. MiR-29a inhibitor, inhibitor negative
control (inhNC), siRNA duplexes target human PTEN and total
Akt [41] were synthesized and purified by RiboBio (Guangzhou,
China). SiRNA duplexes with non-specific sequences were used as
siRNA negative control (NC). Different siRNAs were transfected
separately into cells by using Lipofecatmine 2000 (Invitrogen)
reagent and medium was replaced 6h after transfection.
Construction of plasmids
To construct a plasmid expressing miR-29a, we amplified a
263 bp DNA fragment containing miR-29a precursor from
HepG2 genomic DNA (Table S1). The amplified fragment was
cloned into a pcDNA3.0 vector, which was termed pcDNA3-29a.
The full-length human PTEN expression vector was amplified
from HepG2 cDNA (Table S1), and then cloned into a pcDNA3.0
vector, which was termed pcDNA3-PTEN. An empty pcDNA3.0
vector was used as control (control). To construct 39UTR reporter
plasmids, two ,400 bp fragments of the 39UTR of human PTEN
containing the putative miR-29a binding site were amplified from
HepG2 cells cDNA, and cloned downstream of the luciferase
reporter gene of a pGL3-control vector (Promega). To introduce
four base pair deletion of the seed region of the miR-29a binding
site, we used a PCR approach where the seeds sequences were
deleted in the primers used for PCR reactions (Table S1).
Dual-luciferase reporter gene assay
HepG2 cells were seeded in 24-well plates. After 24 h, cells were
co-transfected with pGL3 control vector containing the 39UTR
Figure 5. Akt phosphorylation is regulated by miR-29a through PTEN. (A, B) The phosphorylation level of Akt (P-Akt) and the expression
level of total Akt (Akt-tot) were detected by Western blot analysis in HepG2 and H7402 cell lines after transfection of miR-29a (or a specific inhibitor).
(C) Western blot analysis showed the phosphorylation of Akt (P-Akt) and the expression of total Akt (Akt-tot) in the cells treated by PTEN siRNA when
the hepatoma cells were transfected with miR-29a inhibitor. Protein bands were quantified using Quantity One software (Bio-Rad). The value under
each lane indicates the relative expression level of PTEN or phosphorylated Akt, which is represented by the intensity ratio between PTEN or
phosphorylated Akt and b-actin or total Akt bands in each lane. (D) A wound healing assay showed that enhanced cell migration by miR-29a was
abolished by Akt siRNA. One representative experiment is shown. Black arrows indicate the wound edge.
doi:10.1371/journal.pone.0019518.g005
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pcDNA3.0 empty plasmid. Luciferase activities were measured 36
h post-transfection using the Dual-Luciferase Reporter Assay
System (Promega). Luciferase activity was normalized for
transfection efficiency using the corresponding Renilla luciferase
activity. All experiments were performed at least three times.
Western blot analysis
Cells were washed in PBS, and cellular proteins were extracted
in RIPA buffer (Biomed, China) for 30 min at 4uC. Lysates were
cleared by centrifugation, and proteins were separated by gel
electrophoresis. Membranes were blocked in PBS-0.1% Tween20
(PBS-T)/5% (w/v) milk for 1 hr at room temperature. Membranes
were then incubated with primary antibodies diluted in PBS-T for
2 hr at room temperature. Subsequently, membranes were washed
with PBS-T and incubated with peroxidase-conjugated secondary
antibody diluted in PBS-T at room temperature for 1 hr.
Membranes were washed in PBS-T and bound antibody was
detected by enhanced chemiluminescence system Western Blotting
Detection Reagents (Amersham Biosciences, Buckinghamshire,
UK). After 48 hr transfection, Western blot analysis was
performed as above; the primary antibodies were anti-PTEN
(Santa Cruz, USA), anti-HBx (Abcam, Cambridge, UK), anti-Akt
(Santa Cruz), anti-phosphorylated Akt (Cell Signaling, USA) and
anti-b-actin (Sigma, USA). All experiments were repeated 3 times.
Protein bands were quantified using Quantity One software (Bio-
Rad).
Wound healing assay
HepG2 cells seeded at 2610
5 in 2 ml of Dulbecco’s modified
Eagle’s medium were cultured overnight at 37uC in 6-well plates.
After 24 hr, transfected cells were wounded by dragging a 1 ml
pipette tip through the monolayer. Cells were washed using PBS to
remove cellular debris and allowed to migrate for 48 hr. Wound
closure or cell migration images were photographed when the
scrape wound was introduced (0 hr) and at a designated time
(48 hr) after wounding using an inverted microscope. The relative
surface traveled by the leading edge was assessed using Motic
Images Advanced 3.2 software. The individual gaps were
measured at each time point, and the speed of migration was
acquired by dividing the length of the gap by the culture time.
Three replicates each of two independent experiments were
performed.
Modified boyden’s chamber assay
Cell migration was assessed using a modified Boyden’s chamber
method as described previously [42]. Briefly, 96-well Boyden’s
chamber was used to measure cell migratory ability and a
polycarbonate membrane with 8-mm pores was used in these
experiments. Cells were resuspended in serum-free DMEM
medium containing 0.2% BSA and were loaded into the upper
wells of the chamber. The lower wells were filled with DMEM
medium containing 10% fetal calf serum as chemoattractant for
cell migration. Cells adhering to the lower membrane were
counted through an inverted microscope.
Statistical analysis
All data were expressed as mean 6 SD. Statistical analysis was
performed by the Student’s t test. P,.05 was indicated to be
statistical significant. Association between expression levels of
miR-29a and PTEN in tissues was explored using Pearson9s
correlation coefficient.
Supporting Information
Figure S1 (A) The relative mRNA expression levels of HBx in
clinical HBV-positive HCC tissues were examined by qRT-PCR.
(B) The relative expression of miR-29a in clinical HBV-positive
HCC tissues was examined by qRT-PCR. Statistically significant
differences are indicated: *P,.05, **P,.01 (Student’s t test).
(TIF)
Figure S2 (A) The expression of miR-29a in MHCC-97H and
MHCC-97L cells was examined by qRT-PCR. (B) Correlation
between miR-29a and PTEN levels in clinical HCC tissues was
analyzed. (C) The expression levels of HBx and PTEN were
detected by Western blot analysis in HepG2, HepG2-P and
HepG2-X (or H7402, H7402-P and H7402-X) cells, respectively.
(D) The expression levels of HBx and PTEN were detected by
Western blot in HepG2-X (or H7402-X) cells after HBx
knockdown by RNAi. (E) The expression of PTEN was detected
by Western blot in MHCC-97L and MHCC-97H cells.
(TIF)
Figure S3 (A) The efficiency of Akt siRNA was detected by
Western blot. (B, C) The expression levels of MMP-1, MMP-2,
MMP-3, MMP-9 and MMP-11 were examined in HepG2 and
H7402 cells transfected with miR-29a by qRT-PCR. (D) The
expression level of MMP-2 mRNA was assessed in HepG2 and
H7402 cells transfected with a specific miR-29a inhibitor by qRT-
PCR. Statistically significant differences are indicated: *P,.05,
**P,.01 (Student’s t test).
(TIF)
Table S1 List of primers used in this paper.
(DOC)
Table S2 The characteristics of patients.
(DOC)
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